Because EGFR overexpression is found in 25 to 82% of colorectal cancer cells, cetuximab-modified nanoparticle carriers could be used as targeting moieties for detecting colorectal cancer cells with EGFR overexpression, as well as for other diagnostic and therapeutic purposes. Here, EGFR is linked to colorectal cancer.